Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALStandard

TIROSINT

LEVOTHYROXINE SODIUM

Standard Dose
0.05MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: N/A Marketing status: Prescription
Summary

Approval overview TIROSINT is listed in Drugs@FDA under application 021924 (NDA).

Review priority: N/A Marketing status: Prescription Active ingredient LEVOTHYROXINE SODIUM Form and strength CAPSULE;ORAL - 0.05MG Sponsor IBSA Submission history Latest submission status date: 2022-06-22 00:00:00.

Structured Monograph

Clinical summary

Approval overview TIROSINT is listed in Drugs@FDA under application 021924 (NDA). Review priority: N/A Marketing status: Prescription Active ingredient LEVOTHYROXINE SODIUM Form and strength CAPSULE;ORAL - 0.05MG Sponsor IBSA Submission history Latest submission status date: 2022-06-22 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: N/A

Interaction Notes

  • No interaction notes stored yet.